<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="GBP" hierarchy="2" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>GB-GOV-10-RP_2019_300791</iati-identifier>
  <reporting-org ref="GB-GOV-10" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">NIHR Global Research Professorships: Developing a melioidosis vaccine targeted for people with type 2 diabetes in low- and middle-income countries</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">The NIHR Global Research Professorship scheme is open to all professions and all Higher Education Institutions (HEI), based in England and the Devolved Administrations, to nominate health researchers and methodologists with an outstanding research record of clinical and applied health research and its effective translation for improved health. Global Research Professors are required to have existing strong collaborations or links with collaborators or partners in institutions in countries on the OECD DAC list and the award should plan to strengthen these/support training and capacity development/mentorship in these partners. 

Melioidosis is a grossly under-recognised tropical disease, caused by bacterium in the soil. Most people with melioidosis are poor and live in rural regions, typically working in rice farming. Ubon in Northeast Thailand is a world hotspot for melioidosis. More than half of melioidosis patients have diabetes, which is rising rapidly in low- and middle-income countries. 

This research will conduct the world&#x2019;s first clinical trial of a new vaccine to prevent melioidosis, targeted for people with diabetes in Thailand and other tropical regions. The laboratory research carried out will identify which biomarkers to use to monitor how the vaccine works in Thailand, and study why people with diabetes are at a greater risk of infections compared to other people.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">The aims of the research are to: 
1.)	evaluate the safety and immunogenicity of a vaccine for melioidosis in people with diabetes in Oxford, UK, and compare immunogenicity with healthy non-diabetic subjects 
2.)	evaluate the safety and immunogenicity of a vaccine for melioidosis in people with and without diabetes in Ubon Ratchathani, Thailand, and compare immunogenicity with UK subjects 
3.)	define the key biomarkers for future monitoring of efficacy of the vaccine for melioidosis using an existing melioidosis patient cohort study 
4.)	undertake a community consultation activity to explore perceptions, understanding and key sensitivities amongst people with diabetes in Ubon, Thailand toward participation in future efficacy trials of a melioidosis vaccine</narrative>
  </description>
  <participating-org ref="GB-GOV-10" role="1" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </participating-org>
  <participating-org ref="GB-GOV-10" role="2" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </participating-org>
  <participating-org ref="GB-GOV-10" role="3" type="10">
   <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Oxford</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2021-06-11" type="1"></activity-date>
  <activity-date iso-date="2021-06-11" type="2"></activity-date>
  <activity-date iso-date="2026-02-26" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">Science, Research and Evidence</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">Global Health Research Programme</narrative>
   </person-name>
   <email>GlobalHealthResearch@dhsc.gov.uk</email>
   <website>https://www.nihr.ac.uk/funding-and-support/global-health-research/</website>
   <mailing-address>
    <narrative xml:lang="EN">7th Floor South Wing, 39 Victoria Street, London, SW1H 0EU</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="789" percentage="100" vocabulary="1"></recipient-region>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="RI" vocabulary="99" vocabulary-uri="https://devtracker.fcdo.gov.uk/custom-codes">
   <narrative xml:lang="EN">Research and Innovation</narrative>
  </tag>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2020-04-01"></period-start>
   <period-end iso-date="2021-03-31"></period-end>
   <value currency="GBP" value-date="2021-06-11">58881</value>
  </budget>
  <budget status="1" type="1">
   <period-start iso-date="2021-04-01"></period-start>
   <period-end iso-date="2022-03-31"></period-end>
   <value currency="GBP" value-date="2021-06-11">378308</value>
  </budget>
  <budget status="1" type="1">
   <period-start iso-date="2022-04-01"></period-start>
   <period-end iso-date="2023-03-31"></period-end>
   <value currency="GBP" value-date="2021-06-11">448780</value>
  </budget>
  <budget status="1" type="1">
   <period-start iso-date="2023-04-01"></period-start>
   <period-end iso-date="2024-03-31"></period-end>
   <value currency="GBP" value-date="2021-06-11">427850</value>
  </budget>
  <budget status="1" type="1">
   <period-start iso-date="2024-04-01"></period-start>
   <period-end iso-date="2025-03-31"></period-end>
   <value currency="GBP" value-date="2021-06-11">368761</value>
  </budget>
  <budget status="1" type="1">
   <period-start iso-date="2025-04-01"></period-start>
   <period-end iso-date="2026-03-31"></period-end>
   <value currency="GBP" value-date="2021-06-11">273741</value>
  </budget>
  <capital-spend percentage="100"></capital-spend>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-09-23"></transaction-date>
   <value currency="GBP" value-date="2021-09-23">241511</value>
   <description>
    <narrative xml:lang="EN">GB-GOV-10-RP_2019_300791 2021/22 Q2 DISBURSEMENT</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-10-RP_2019_300791" ref="GB-GOV-10">
    <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-11-17"></transaction-date>
   <value currency="GBP" value-date="2021-11-17">91814</value>
   <description>
    <narrative xml:lang="EN">GB-GOV-10-RP_2019_300791 2021/22 Q3 DISBURSEMENT</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-10-RP_2019_300791" ref="GB-GOV-10">
    <narrative xml:lang="EN">UK - Department of Health and Social Care (DHSC)</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">University of Oxford</narrative>
   </receiver-org>
  </transaction>
  <conditions attached="0"></conditions>
 </iati-activity>
</iati-activities>
